Sawsan Rashdan

Sawsan Rashdan

UNVERIFIED PROFILE

Are you Sawsan Rashdan?   Register this Author

Register author
Sawsan Rashdan

Sawsan Rashdan

Publications by authors named "Sawsan Rashdan"

Are you Sawsan Rashdan?   Register this Author

7Publications

86Reads

43Profile Views

QTc Interval-Prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care.

Clin Lung Cancer 2020 Jan 25;21(1):21-27.e5. Epub 2019 Nov 25.

Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX; Division of Hematology-Oncology, UT Southwestern Medical Center, Dallas, TX; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX; Department of Population and Data Sciences, UT Southwestern Medical Center, Dallas, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.07.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937372PMC
January 2020

Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice.

Transl Lung Cancer Res 2019 Jun;8(3):202-207

Division of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2018.09.15DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626864PMC
June 2019

Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy.

Lancet Respir Med 2018 06;6(6):472-478

Division of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA; Harold C Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(18)30172-3DOI Listing
June 2018

A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.

Transl Cancer Res 2017 Feb;6(Suppl 1):S78-S82

Department of Internal Medicine (Division of Hematology-Oncology), Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center. Dallas, Texas. USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tcr.2017.02.12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495191PMC
February 2017

Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies.

Ann Transl Med 2016 Dec;4(24):529

Division of Hematology-Oncology, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2016.12.57DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5233507PMC
December 2016

Salvage Therapy for Patients With Germ Cell Tumor.

J Oncol Pract 2016 05;12(5):437-43

Melvin Bren Simon Cancer Center, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2016.011411DOI Listing
May 2016

Nintedanib for the treatment of non-small-cell lung cancer.

Expert Opin Pharmacother 2014 Apr 5;15(5):729-39. Epub 2014 Mar 5.

Indiana University, Indiana Cancer Pavilion, Hematology and Oncology , 535 Barnhill Dr. 473, Indianapolis, IN 46202 , USA +1 317 944 5000 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2014.897695DOI Listing
April 2014